NCT04076449Recruiting
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Quantitative Susceptibility Mapping Biomarker, Brain Structure and Connectome Associated With Cerebral Cavernous Malformation Related Epilepsy and Outcome After Surgery
Source: ClinicalTrials.gov · Last updated 4 Sept 2019 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Cerebral cavernous malformation (CCM)-related epilepsy (CRE) impairs the quality of life in patients with CCM. Patients could not always achieve seizure freedom after surgical resection of the lesion, suggesting an inadequate treatment and evaluation of the epileptogenic zone or network. Iron deposition in cerebral cavernous malformations has been postulated to play an important role in triggering CRE. Quantitative susceptibility mapping (QSM), as an optimal in vivo imaging technique to quantify iron deposition, is employed to analyze the iron quantity in CCM patients with epilepsy and further combined with brain structural and connectome analysis, to describe the difference between CCMs with and without epilepsy. In vivo biomarkers predicting CRE risk in CCM natural history and CRE control outcome after CCM surgical resection will be further identified to improve management strategy.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 29 Aug 2019
- Start date
- 3 Sept 2019
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- yuanli Zhao
- Diseases
- Epilepsy
- NCT number
- NCT04076449
What you commit to
- Study type: Observational
- Planned participants: 200
- From 3 Sept 2019 to the primary completion date, 31 Dec 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- (2) History of previous intracranial surgery
- (3) Prior brain irradiation
Other illness
- (7) Dementia or other progressive neurological disease
Other
- (1) Associated with brain lesions and/or tumors other than CCM
- (4) Contraindication or unwilling or unable to undergo research MRI studies
- (5) Pregnant or breastfeeding women
- (6) Persons unable or unlikely to return for follow-up visits
Who the study is looking for
- (1) 18 to 70 years of age
- (2) Diagnosed with a single cerebral cavernous malformation
- (3) No prior treatment of the symptomatic lesion
Age in the registry: 18 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Tiantan Hospital,Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| Peking University International Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.